BR9911365A - Compostos pirrolo[2,3-d]pirimidina - Google Patents

Compostos pirrolo[2,3-d]pirimidina

Info

Publication number
BR9911365A
BR9911365A BR9911365-1A BR9911365A BR9911365A BR 9911365 A BR9911365 A BR 9911365A BR 9911365 A BR9911365 A BR 9911365A BR 9911365 A BR9911365 A BR 9911365A
Authority
BR
Brazil
Prior art keywords
diabetes
disease
pyrrolo
pyrimidine compounds
pyrimidine
Prior art date
Application number
BR9911365-1A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Mark Edward Flanagan
Matthew Frank Brown
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26781018&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9911365(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9911365A publication Critical patent/BR9911365A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Abstract

Patente de Invenção: <B>"COMPOSTOS PIRROLO[2,3-d]PIRIMIDINA"<D>. Composto com a fórmula na qual R¹, R² e R³ são como anteriormente definidos, que são inibidores das enzimas proteína tirosina quinases tal como Janus Kinase 3 e como tal são uma terapia útil como agentes imunossupressivos para transplantes de órgãos, lúpus, esclerose múltipla, artrite reumatóide, psoríase, diabetes do Tipo I e complicações de diabetes, cancêr, asma, dermatite atópica, doenças da tiróide auto-imunes, colite ulcerativa, doença de Crohn, doença de Alzheimer, leucemia e outras doenças auto-imunes.
BR9911365-1A 1998-06-19 1999-06-14 Compostos pirrolo[2,3-d]pirimidina BR9911365A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8986698P 1998-06-19 1998-06-19
US10478798P 1998-10-19 1998-10-19
PCT/IB1999/001100 WO1999065908A1 (en) 1998-06-19 1999-06-14 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS

Publications (1)

Publication Number Publication Date
BR9911365A true BR9911365A (pt) 2001-03-13

Family

ID=26781018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911365-1A BR9911365A (pt) 1998-06-19 1999-06-14 Compostos pirrolo[2,3-d]pirimidina

Country Status (41)

Country Link
US (3) US6610847B2 (pt)
EP (1) EP1087970B1 (pt)
JP (3) JP4666762B2 (pt)
KR (1) KR100415791B1 (pt)
CN (1) CN1128800C (pt)
AP (1) AP1021A (pt)
AR (1) AR016499A1 (pt)
AT (1) ATE265458T1 (pt)
AU (1) AU3951899A (pt)
BG (1) BG65119B1 (pt)
BR (1) BR9911365A (pt)
CA (1) CA2335492C (pt)
CZ (1) CZ20004727A3 (pt)
DE (1) DE69916833T2 (pt)
DK (1) DK1087970T3 (pt)
EA (1) EA005852B1 (pt)
ES (1) ES2219018T3 (pt)
FR (1) FR14C0019I2 (pt)
GE (1) GEP20074227B (pt)
GT (1) GT199900090A (pt)
HK (1) HK1036801A1 (pt)
HR (1) HRP20000885B1 (pt)
HU (1) HUP0102574A3 (pt)
ID (1) ID26698A (pt)
IL (1) IL139586A0 (pt)
MA (1) MA26654A1 (pt)
MY (1) MY125916A (pt)
NO (1) NO318784B1 (pt)
NZ (1) NZ518444A (pt)
OA (1) OA11572A (pt)
PA (1) PA8476001A1 (pt)
PE (1) PE20000698A1 (pt)
PL (1) PL198640B1 (pt)
PT (1) PT1087970E (pt)
RS (1) RS50087B (pt)
SA (1) SA99200283B1 (pt)
SK (1) SK286640B6 (pt)
TN (1) TNSN99126A1 (pt)
TR (1) TR200003719T2 (pt)
TW (1) TW505646B (pt)
WO (1) WO1999065908A1 (pt)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HUP0102574A3 (en) * 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
PL359920A1 (en) 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
DE10063294A1 (de) * 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
NZ526961A (en) 2001-02-12 2005-03-24 F 6-substituted pyrido-pyrimidines
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
PT1401413E (pt) 2001-06-29 2007-02-28 Ab Science Uso de inibidores da tirosina cinase para tratar doenças alérgicas
CA2452361A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
CN1717236A (zh) * 2002-11-26 2006-01-04 辉瑞产品公司 治疗移植排斥的方法
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006004703A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
AU2006247757B2 (en) 2005-05-13 2009-08-27 Irm, Llc Compounds and compositions as protein kinase inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CA2615291A1 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
ES2401192T3 (es) 2005-09-30 2013-04-17 Vertex Pharmceuticals Incorporated Deazapurinas útiles como inhibidores de janus cinasas
PL2474545T3 (pl) 2005-12-13 2017-04-28 Incyte Holdings Corporation Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
EP2123651A4 (en) 2007-01-12 2011-05-04 Astellas Pharma Inc CONDENSED PYRIDINE COMPOUND
KR20100015353A (ko) * 2007-04-02 2010-02-12 팔라우 파르마 에스에이 Ｊａｋ３ 억제제로서의 피롤로피리미딘 유도체
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
MX2010005116A (es) * 2007-11-10 2010-09-09 Landmark Graphics Corp Sistemas y metodos para automatizacion, adaptacion e integracion del flujo de trabajo.
EP3912973A3 (en) * 2007-11-28 2022-02-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
NZ587271A (en) 2008-02-06 2012-03-30 Novartis Ag Pyrrolo[2,3-d]pyrimidines containing a 7h-pyrrolo[2,3-d]pyrimidin-2-yl core and use thereof as tyrosine kinase inhibitors
PT2247592E (pt) * 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
AU2009223640B2 (en) 2008-03-11 2013-07-04 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
WO2009115084A2 (de) * 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CA2728559A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
KR20110050654A (ko) * 2008-08-01 2011-05-16 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Ｊａｋ3 억제제로서의 피페리딘 유도체
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
BRPI1007737A2 (pt) 2009-04-20 2015-09-01 Auspex Pharmaceuticals Llc "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (zh) 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
JP5629324B2 (ja) 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CN102822177A (zh) 2010-02-05 2012-12-12 美国辉瑞有限公司 吡咯并[2,3-d]嘧啶脲化合物
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
AR081315A1 (es) 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
TW201204732A (en) * 2010-07-09 2012-02-01 Leo Pharma As Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CA2823935A1 (en) 2011-01-07 2012-07-12 Leo Pharma A/S Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
PL2675451T3 (pl) 2011-02-18 2016-05-31 Novartis Pharma Ag Terapia skojarzona z inhibitorem mTOR/JAK
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
AU2012255792A1 (en) * 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
EP2796460B1 (en) * 2011-12-21 2018-07-04 Jiangsu Hengrui Medicine Co. Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP3255049A1 (en) * 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
PL2875013T3 (pl) * 2012-07-17 2018-06-29 Glaxosmithkline Intellectual Property (No. 2) Limited Indolokarbonitryle jako selektywne modulatory receptora androgenowego
MX360857B (es) * 2012-07-20 2018-11-20 Zoetis Llc Régimen de dosificación para inhibidores de janus quinasa (jak).
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2897962A1 (en) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
KR101683061B1 (ko) * 2013-02-07 2016-12-07 한국과학기술연구원 ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
LT3290421T (lt) * 2013-02-22 2019-02-25 Pfizer Inc. Pirolo [2, 3 -d]pirimidino darinių derinys su vienu arba daugiau papildomų agentų, kaip janus kinazės (jak) inhibitorių
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
EP2970119B1 (en) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
MX2016001639A (es) 2013-08-07 2016-10-07 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
HUE054560T2 (hu) 2013-12-05 2021-09-28 Pfizer Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
EP3288943B1 (en) 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
JP6564473B2 (ja) * 2015-05-29 2019-08-21 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｎｕｓキナーゼ阻害剤
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
AU2017221193B2 (en) 2016-02-16 2019-03-14 Zoetis Services Llc Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
EP3555074B1 (en) 2016-12-14 2022-07-27 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
TW202043205A (zh) * 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
CN113993585A (zh) 2019-03-27 2022-01-28 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117242080A (zh) 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023118555A1 (en) 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds
GB202215132D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound
GB202215117D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
DK0831829T3 (da) * 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
US6066638A (en) 1995-07-05 2000-05-23 E. I. Du Pont De Nemours And Company Fungicidal pyrimidinones
TR199800012T1 (xx) * 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA000072B1 (ru) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента
WO1997027199A1 (en) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69738468T2 (de) * 1996-08-23 2009-01-08 Novartis Ag Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
KR20000057228A (ko) * 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 축합된 비사이클릭 피리미딘 유도체
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
AU6568398A (en) 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
US6080847A (en) * 1997-12-04 2000-06-27 Incyte Pharmaceuticals, Inc. Proteins associated with cell proliferation
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
EP1082311A1 (en) 1998-05-28 2001-03-14 Parker Hughes Institute Quinazolines for treating brain tumor
HUP0102574A3 (en) * 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
AU2009100870A4 (en) 2008-10-01 2009-10-22 Rock Tone Enterprise Co., Ltd. Drive mechanism for dehydrator
TWM358618U (en) 2008-12-26 2009-06-11 Rock Tone Entpr Co Ltd Combination structure of mop holder and cleaning body

Also Published As

Publication number Publication date
HUP0102574A3 (en) 2002-01-28
IL139586A0 (en) 2002-02-10
HRP20000885B1 (en) 2007-03-31
US6610847B2 (en) 2003-08-26
WO1999065908A1 (en) 1999-12-23
HRP20000885A2 (en) 2001-10-31
JP4971068B2 (ja) 2012-07-11
FR14C0019I2 (fr) 2015-01-02
US7687507B2 (en) 2010-03-30
FR14C0019I1 (pt) 2014-04-11
EP1087970A1 (en) 2001-04-04
CA2335492C (en) 2005-05-17
ID26698A (id) 2001-02-01
PL345123A1 (en) 2001-12-03
EA200001203A1 (ru) 2001-06-25
JP4666762B2 (ja) 2011-04-06
JP2002518393A (ja) 2002-06-25
TNSN99126A1 (fr) 2005-11-10
GT199900090A (es) 2000-12-09
ES2219018T3 (es) 2004-11-16
EP1087970B1 (en) 2004-04-28
HK1036801A1 (en) 2002-01-18
SK18982000A3 (sk) 2002-08-06
EA005852B1 (ru) 2005-06-30
BG65119B1 (bg) 2007-03-30
SA99200283B1 (ar) 2006-03-25
ATE265458T1 (de) 2004-05-15
YU78500A (sh) 2003-04-30
TR200003719T2 (tr) 2001-03-21
HUP0102574A2 (hu) 2001-11-28
PA8476001A1 (es) 2003-09-05
JP2012041365A (ja) 2012-03-01
CZ20004727A3 (cs) 2002-03-13
KR20010053004A (ko) 2001-06-25
NO318784B1 (no) 2005-05-09
PL198640B1 (pl) 2008-07-31
MY125916A (en) 2006-08-30
DE69916833T2 (de) 2005-04-14
CA2335492A1 (en) 1999-12-23
RS50087B (sr) 2009-01-22
BG105129A (en) 2001-11-30
AP1021A (en) 2001-11-09
NZ518444A (en) 2004-04-30
US20030212273A1 (en) 2003-11-13
GEP20074227B (en) 2007-10-25
DE69916833D1 (de) 2004-06-03
US20020019526A1 (en) 2002-02-14
AP9901584A0 (en) 1999-06-30
MA26654A1 (fr) 2004-12-20
CN1305480A (zh) 2001-07-25
AU3951899A (en) 2000-01-05
CN1128800C (zh) 2003-11-26
NO20006453L (no) 2001-02-05
SK286640B6 (sk) 2009-03-05
US20050171128A1 (en) 2005-08-04
OA11572A (en) 2004-07-01
AR016499A1 (es) 2001-07-04
KR100415791B1 (ko) 2004-01-24
JP2007284455A (ja) 2007-11-01
PT1087970E (pt) 2004-06-30
TW505646B (en) 2002-10-11
PE20000698A1 (es) 2000-08-19
NO20006453D0 (no) 2000-12-18
DK1087970T3 (da) 2004-08-02
US6890929B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
BR9911365A (pt) Compostos pirrolo[2,3-d]pirimidina
BR9912171A (pt) Compostos de pirrolo[2,3-d]pirimidina
BR0016263A (pt) Compostos pirrolo[2,3-d]pirimidina
YU83302A (sh) Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
BR0215308A (pt) Pirrolopirimidinas
WO2000035906A3 (en) 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
CO5470282A1 (es) Union soldada de tubos metalicos, anillo separador para la realizacion de dicha union soldada y uso de dicho anillo separador
ECSP992964A (es) COMPUESTO DE PIRROLO (2,3 -d) PIRIMIDA
ECSP993019A (es) COMPUESTOS DE PIRROLO [2,3-d] PIRIMIDINA
HN1999000092A (es) Compuestos de pirrolo (2,3-d)pirimidina
NO20050202L (no) Pyrrolo(2,3-d)pyrimidinforbindelser
UY26791A1 (es) Compuestos de pirrol (2,3-d) pirimidina

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 487/04, C07D 519/00, A61K 31/519, A61P 1/04, A61P 3/10, A61P 5/14, A61P 11/06, A61P 17/00, A61P 17/04, A61P 19/02, A61P 25/00, A61P 25/28, A61P 29/00, A61P 35/00, A61P 35/02, A61P 37/06

Ipc: C07D 487/04 (2009.01), C07D 519/00 (2009.01), A61K

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements